A single enzyme that can generate all four nucleoside triphosphates, the building blocks of ribonucleic acid (RNA), has been ...

Designed to balance ease of use, cost efficiency, and reproducible data, which are critical requirements for successful ...

Dr Mark Kris discusses the increasing precision of lung cancer therapies and the need for additional testing to find ...

The Global Mantle Cell Lymphoma Market offers significant growth potential driven by an aging population increasing cancer ...

Early Phase I data showed inhaled londamocitinib reduced airway inflammation in mild asthma with good tolerability. Learn more about this novel approach.

A U.S.-based clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The company conducts ...

The FDA granted orphan drug designation to zavabresib, an investigational therapy for the treatment of myelofibrosis, a rare ...

Eligible women with breast cancer in Thailand now have access to a new therapy, NERLYNX® (neratinib), for the first timeThe launch of NERLYNX provides an ...

Discover the challenges of acute myeloid leukaemia linked to inflammatory cell death and the quest for effective therapies.

year survival rates averaged across all cancers have never been higher, with 7-in-10 cancer patients living past 5 years post-diagnosis.

Lexicon Pharmaceuticals, Inc. is downgraded to Hold due to repeated FDA rejections of ZYNQUISTA for T1D and catalysts. Read more on LXRX stock here.

Illumina secures CMS reimbursement for TruSight Oncology Comprehensive, expanding access to precision oncology: San Diego Thursday, January 22, 2026, 17:00 Hrs [IST] Illumina, Inc ...